Skip to main content Accessibility help
×
Home
Hostname: page-component-55597f9d44-l69ms Total loading time: 1.001 Render date: 2022-08-14T19:14:23.617Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true } hasContentIssue true

Chapter 15 - Population pharmacokinetics of antipsychotics

Published online by Cambridge University Press:  03 May 2010

T. Scott Stroup
Affiliation:
Columbia University, New York
Jeffrey A. Lieberman
Affiliation:
Columbia University, New York
Get access

Summary

The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trials afforded a unique opportunity to study a large number of patients treated with antipsychotics. This ancillary study to the CATIE trials aimed to evaluate the magnitude and variability of concentration exposure of antipsychotics using mixed-effects population pharmacokinetic methodologies. Patients with Alzheimer's disease (AD) were treated with oral olanzapine, risperidone, quetiapine, or citalopram. Patients with schizophrenia (SZ) were treated with oral olanzapine, risperidone, quetiapine, perphenazine, ziprasidone, clozapine, aripiprazole, or fluphenazine decanoate, or a combination of medications. The population pharmacokinetic analysis included the development of a structural base model, which defines the pharmacokinetic parameters and describes the plasma concentration-time profile for each drug. Identifying factors that contribute to the variability in the pharmacokinetics of a drug is not only important in predicting a clinical response but also in order to avoid possible adverse events.
Type
Chapter
Information
Antipsychotic Trials in Schizophrenia
The CATIE Project
, pp. 267 - 280
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
1
Cited by

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×